Report Detail
Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4769102 |
- 06 November, 2026 |
- Global |
- 85 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Monoclonal antibody anti-VEGF ophthalmic drugs are a class of medications specifically engineered to target and neutralize vascular endothelial growth factor(VEGF),a key protein involved in angiogenesis and vascular permeability in the eye.These drugs are administered via intravitreal injection directly into the eye to treat diseases like wet age-related macular degeneration(AMD),diabetic retinopathy,and macular edema.
This report is a detailed and comprehensive analysis for global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Novartis, Coherus BioSciences, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Faricimab
Brolucizumab
Brolucizumab
Other
Market segment by Application
Age-related Macular Degeneration
Diabetic Retinopathy
Other
Major players covered
Roche
Novartis
Coherus BioSciences
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, with price, sales quantity, revenue, and global market share of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs from 2021 to 2026.
Chapter 3, the Monoclonal Antibody Anti-VEGF Ophthalmic Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Monoclonal Antibody Anti-VEGF Ophthalmic Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs.
Chapter 14 and 15, to describe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Faricimab
- 1.3.3 Brolucizumab
- 1.3.4 Brolucizumab
- 1.3.5 Other
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Age-related Macular Degeneration
- 1.4.3 Diabetic Retinopathy
- 1.4.4 Other
- 1.5 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size & Forecast
- 1.5.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumption Value (2021 & 2025 & 2032)
- 1.5.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity (2021-2032)
- 1.5.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Roche
- 2.1.1 Roche Details
- 2.1.2 Roche Major Business
- 2.1.3 Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product and Services
- 2.1.4 Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Roche Recent Developments/Updates
- 2.2 Novartis
- 2.2.1 Novartis Details
- 2.2.2 Novartis Major Business
- 2.2.3 Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product and Services
- 2.2.4 Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Novartis Recent Developments/Updates
- 2.3 Coherus BioSciences
- 2.3.1 Coherus BioSciences Details
- 2.3.2 Coherus BioSciences Major Business
- 2.3.3 Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product and Services
- 2.3.4 Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Coherus BioSciences Recent Developments/Updates
3 Competitive Environment: Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Manufacturer
- 3.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Manufacturer (2021-2026)
- 3.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Manufacturer Market Share in 2025
- 3.4.3 Top 6 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Manufacturer Market Share in 2025
- 3.5 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market: Overall Company Footprint Analysis
- 3.5.1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market: Region Footprint
- 3.5.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market: Company Product Type Footprint
- 3.5.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Region
- 4.1.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity by Region (2021-2032)
- 4.1.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumption Value by Region (2021-2032)
- 4.1.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Average Price by Region (2021-2032)
- 4.2 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumption Value (2021-2032)
- 4.3 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumption Value (2021-2032)
- 4.4 Asia-Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumption Value (2021-2032)
- 4.5 South America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumption Value (2021-2032)
- 4.6 Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity by Type (2021-2032)
- 5.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumption Value by Type (2021-2032)
- 5.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity by Application (2021-2032)
- 6.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumption Value by Application (2021-2032)
- 6.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Average Price by Application (2021-2032)
7 North America
- 7.1 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity by Type (2021-2032)
- 7.2 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity by Application (2021-2032)
- 7.3 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country
- 7.3.1 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity by Country (2021-2032)
- 7.3.2 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity by Type (2021-2032)
- 8.2 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity by Application (2021-2032)
- 8.3 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country
- 8.3.1 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Region
- 9.3.1 Asia-Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity by Type (2021-2032)
- 10.2 South America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity by Application (2021-2032)
- 10.3 South America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country
- 10.3.1 South America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity by Country (2021-2032)
- 10.3.2 South America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country
- 11.3.1 Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Drivers
- 12.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Restraints
- 12.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
- 13.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Typical Distributors
- 14.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Monoclonal Antibody Anti-VEGF Ophthalmic Drugs. Industry analysis & Market Report on Monoclonal Antibody Anti-VEGF Ophthalmic Drugs is a syndicated market report, published as Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
